keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28635336/new-advances-in-focal-therapy-for-early-stage-prostate-cancer
#1
Kae Jack Tay, Ariel A Schulman, Christina Sze, Efrat Tsivian, Thomas J Polascik
Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas Covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28632693/extraosseous-extension-of-aggressive-vertebral-hemangioma-as-a-potential-pitfall-on-68ga-psma-pet-ct
#2
Stephan Probst, Franck Bladou, Gad Abikhzer
A 74-year-old man with newly diagnosed prostate cancer underwent Ga-PSMA PET/CT, which demonstrated intense uptake in and adjacent the L2 vertebral body. Subsequent MRI of the lumbar spine showed an aggressive L2 hemangioma with adjacent soft tissue extension. There was congruence of the intraosseous and extraosseous components of the hemangioma and the PSMA PET uptake. This is a rare but important potential pitfall in Ga-PSMA PET/CT-a soft tissue lesion with intense tracer uptake related not to a nodal metastasis of prostate cancer but to extraosseous extension of an aggressive vertebral body hemangioma...
June 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28624849/the-accuracy-of-68-ga-psma-pet-ct-in-primary-lymph-node-staging-in-high-risk-prostate-cancer
#3
Can Öbek, Tünkut Doğanca, Emre Demirci, Meltem Ocak, Ali Rıza Kural, Asıf Yıldırım, Uğur Yücetaş, Çetin Demirdağ, Sarper M Erdoğan, Levent Kabasakal
PURPOSE: To assess the diagnostic accuracy of (68)Ga-PSMA PET in predicting lymph node (LN) metastases in primary N staging in high-risk and very high-risk nonmetastatic prostate cancer in comparison with morphological imaging. METHODS: This was a multicentre trial of the Society of Urologic Oncology in Turkey in conjunction with the Nuclear Medicine Department of Cerrahpasa School of Medicine, Istanbul University. Patients were accrued from eight centres. Patients with high-risk and very high-risk disease scheduled to undergo surgical treatment with extended LN dissection between July 2014 and October 2015 were included...
June 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28624848/-177-lu-psma-617-radioligand-therapy-and-outcome-in-patients-with-metastasized-castration-resistant-prostate-cancer
#4
Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, Andres Jan Schrader, Michael Schäfers, Martin Bögemann, Kambiz Rahbar
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to evaluate the overall survival (OS) and to identify parameters predicting outcome in mCRPC patients treated with (177)Lu-PSMA-617. METHODS: Between December 2014 and January 2017, 59 consecutive patients (median age 72 years; interquartile range, (IQR, 66-76 years) with mCRPC, who had been treated with at least one next-generation antihormonal drug as well as chemotherapy, were included in this study...
June 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28623872/uptake-in-sympathetic-ganglia-on-68-ga-psma-hbed-pet-ct-a-potential-pitfall-in-scan-interpretation
#5
Gowri L Kanthan, Edward Hsiao, Dzung Vu, Geoffrey Paul Schembri
INTRODUCTION: The aim of this study was to assess the frequency of PSMA-HBED uptake in coeliac and stellate ganglia in patients presenting for PSMA-HBED PET/CT scan. METHODS: Prostate-specific membrane antigen-HBED PET/CT scans of 100 consecutive patients were analysed. Coeliac and stellate ganglia were identified by their anatomical location. PSMA-HBED uptake in these ganglia was recorded as either present or absent. If present, the SUVmax value for each ganglion was measured and compared to SUVmax of mediastinal blood pool...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28623852/frusemide-aids-diagnostic-interpretation-of-68-ga-psma-positron-emission-tomography-ct-in-men-with-prostate-cancer
#6
Niall Fennessy, Jonathan Lee, Jane Shin, Bao Ho, Syed Aman Ali, Royce Paschkewitz, Louise Emmett
INTRODUCTION: (68) Ga-PSMA positron emission tomography-computed tomography (PET/CT) is useful for both staging and assessment of biochemical relapse in men with prostate cancer. Renal excretion of (68) Ga-PSMA can lead to difficulties in scan interpretation, particularly in the pelvis. We evaluated if intravenous Frusemide at the time of (68) Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty. METHODS: Sixty-two men with prostate cancer undergoing clinically indicated (68) Ga-PSMA PET/CT were prospectively included, 30 men receiving Frusemide at the time of radiotracer injection...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28619734/-68-ga-psma11-pet-ct-in-newly-diagnosed-carcinoma-of-the-prostate-correlation-of-intraprostatic-psma-uptake-with-several-clinical-parameters
#7
Stefan A Koerber, Maximilian T Utzinger, Clemens Kratochwil, Claudia Kesch, Matthias Haefner, Sonja Katayama, Walter Mier, Andrei H Iagaru, Klaus Herfarth, Uwe Haberkorn, Juergen Debus, Frederik L Giesel
(68)Ga-prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/ computer tomography (CT) is a promising diagnostic tool for patients with prostate cancer. Our study evaluates standardized uptake values (SUV) in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred and four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. Maximum SUV (SUVmax) was measured and correlated with biopsy findings and magnetic resonance imaging (MRI)...
June 15, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28618401/64cu-psma-617-a-novel-psma-targeted-radio-tracer-for-pet-imaging-in-gastric-adenocarcinoma-xenografted-mice-model
#8
Xue-di Han, Chen Liu, Fei Liu, Qing-Hua Xie, Te-Li Liu, Xiao-Yi Guo, Xiao-Xia Xu, Xing Yang, Hua Zhu, Zhi Yang
Here, we report that it's feasible for imaging gastric adenocarcinoma mice model with prostate-specific membrane antigen (PSMA) targeting imaging agents, which could potentially provide an alternate and readily translational tool for managing gastric adenocarcinoma. DKFZ-PSMA-617, a PSMA targeting ligand reported recently, was chosen to be radio-labeled with nuclide 64Cu. 64Cu-PSMA-617 was radio-synthesized in high radio-chemical yield and specific activity up to 19.3 GBq/μmol. It showed good stability in vitro...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28613198/lu-177-psma-617-prostate-specific-membrane-antigen-inhibitor-therapy-in-patients-with-castration-resistant-prostate-cancer-stability-bio-distribution-and-dosimetry
#9
Levent Kabasakal, Türkay Toklu, Nami Yeyin, Emre Demirci, Mohammad Abuqbeitah, Meltem Ocak, Aslan Aygün, Emre Karayel, Hüseyin Pehlivanoğlu, Nalan Alan Selçuk
OBJECTIVE: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617. METHODS: For this purpose, 7 patients who underwent Lu-177-PSMA therapy were included into the study. The injected Lu-177-PSMA-617 activity ranged from 3.6 to 7.4 GBq with a mean of 5.2±1.8 GBq. The stability of radiotracer in saline was calculated up to 48 h...
June 1, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28608163/prostate-specific-membrane-antigen-pet-mri-validation-of-mr-textural-analysis-for-detection-of-transition-zone-prostate-cancer
#10
Anthony Bates, Kenneth Miles
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR. METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis...
June 12, 2017: European Radiology
https://www.readbyqxmd.com/read/28607878/targeted-prostate-biopsy-using-68-gallium-psma-pet-ct-for-image-guidance
#11
Demetrios N Simopoulos, Shyam Natarajan, Tonye A Jones, Wolfgang P Fendler, Anthony E Sisk, Leonard S Marks
Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a (68)Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusion technology, the lesion was target-biopsied and Gleason 3 + 4 = 7 (cancer core length of 12 mm) was identified. This case may herald a new application for PSMA scanning and prostate cancer imaging.
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28598898/a-99mtc-labelled-scfv-antibody-fragment-that-binds-to-prostate-specific-membrane-antigen
#12
Saima Nawaz, Gregory E D Mullen, Philip J Blower, James R Ballinger
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an extensively studied antigen for imaging prostate cancer. We prepared a single-chain variable fragment (scFv) of J591, a monoclonal antibody that recognises an external epitope of PSMA, incorporating a His-tag for labelling with Tc tricarbonyl, and evaluated its binding using human PCa cell lines. METHODS: J591(scFv) was expressed in HEK-293T cells and purified by metal ion affinity chromatography, followed by size exclusion chromatography...
June 8, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28597119/highlights-lecture-eanm-2016-embracing-molecular-imaging-and-multi-modal-imaging-a-smart-move-for-nuclear-medicine-towards-personalized-medicine
#13
REVIEW
Eric O Aboagye, Françoise Kraeber-Bodéré
The 2016 EANM Congress took place in Barcelona, Spain, from 15 to 19 October under the leadership of Prof. Wim Oyen, chair of the EANM Scientific Committee. With more than 6,000 participants, this congress was the most important European event in nuclear medicine, bringing together a multidisciplinary community involved in the different fields of nuclear medicine. There were over 600 oral and 1,200 poster or e-Poster presentations with an overwhelming focus on development and application of imaging for personalized care, which is timely for the community...
June 8, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28593386/prostate-specific-membrane-antigen-pet-imaging-and-immunohistochemistry-in-adenoid-cystic-carcinoma-%C3%AF-a-preliminary-analysis
#14
Thomas J W Klein Nulent, Robert J J van Es, Gerard C Krijger, Remco de Bree, Stefan M Willems, Bart de Keizer
BACKGROUND: Adenoid cystic carcinoma (AdCC) of the head and neck is an uncommon malignant epithelial tumour of the secretory glands. Many patients develop slowly growing local recurrence and/or distant metastasis, for which treatment options are limited. A retrospective analysis of 9 AdCC patients was conducted to analyse the visualization of AdCC on PSMA PET/CT and to investigate the expression of PSMA on primary, recurrent and metastatic AdCC tumour tissue using immunohistochemistry...
June 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28590314/novel-imaging-in-advanced-prostate-cancer
#15
Hanan Goldberg, Robert J Hamilton
PURPOSE OF REVIEW: Prostate cancer (PCa) is the most commonly diagnosed noncutaneous cancer and second leading cause of death in men. Imaging evaluation of PCa is challenging because of the prostate's deep pelvic location, its complex zonal anatomy and its multifocal nature. Novel imaging modalities are needed to improve detection, reassessment in biochemical relapse, and disease progression in advanced metastatic stages. RECENT FINDINGS: Current imaging modalities have distinct strengths...
June 3, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28590295/68ga-psma-pet-mr-positive-peritoneal-metastasis-in-the-falciform-ligament-in-recurrent-prostate-cancer
#16
Benedikt Kranzbühler, Sébastien Tran, Thomas Zilli, Irene A Burger
Synchronous or metachronous metastases develop in approximately one third of all prostate cancer (PCa) patients. Main sites of metastasis include lymph nodes, bone, lung and liver. Secondary peritoneal carcinomatosis is very rare in PCa, with only a few published cases. Ga-PSMA PET-based imaging is a promising tool for staging and restaging PCa. We report a case of Ga-PSMA PET/MR-positive peritoneal metastasis as site of primary relapse after definitive PCa treatment in a 58-year-old man with a prostate-specific antigen of 30 ng/mL at time of the study...
June 5, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28589253/early-pet-imaging-with-68-ga-psma-11-increases-the-detection-rate-of-local-recurrence-in-prostate-cancer-patients-with-biochemical-recurrence
#17
Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, Clemens Decristoforo, Dorota Kendler, Elisabeth von Guggenberg, Bernhard Nilica, Johanna Maffey-Steffan, Gianpaolo di Santo, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: PET/CT using (68)Ga-labelled prostate-specific membrane antigen PSMA-11 (HBEDD-CC) has emerged as a promising imaging method in the diagnostic evaluation of prostate cancer (PC) patients with biochemical recurrence. However, assessment of local recurrence (LR) may be limited by intense physiologic tracer accumulation in the urinary bladder on whole-body scans, normally conducted 60 min post-tracer injection (p.i.). It could be shown on early dynamic imaging studies that (68)Ga-PSMA-11 uptake in PC lesions occurs earlier than tracer accumulation in the urinary bladder...
June 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28588059/near-infrared-photoimmunotherapy-targeting-prostate-cancer-with-prostate-specific-membrane-antigen-psma-antibody
#18
Tadanobu Nagaya, Yuko Nakamura, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Peter L Choyke, Hisataka Kobayashi
Prostate-specific membrane antigen (PSMA) is a membrane protein that is overexpressed manifold in prostate cancer and provides an attractive target for molecular therapy. Near infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate (APC). Here, we describe the efficacy of NIR-PIT, using a fully human IgG1 anti-PSMA monoclonal antibody (mAb), conjugated to the photo-absorber, IR700DX, in a PSMA expressing PC3 prostate cancer cell line. Anti-PSMA-IR700 showed specific binding and cell-specific killing was observed after exposure of the cells to NIR in vitro...
June 6, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28577076/-68-ga-psma-11-pet-ct-the-rising-star-of-nuclear-medicine-in-prostate-cancer-imaging
#19
Christian Uprimny
Ever since the introduction of (68)Ga-prostate-specific membrane antigen 11 positron-emission tomography/computed tomography ((68)Ga-PSMA-11 PET/CT) a few years ago, it has rapidly achieved great success in the field of prostate cancer imaging. A large number of studies have been published to date, indicating a high potential of (68)Ga-PSMA-11 PET/CT in the work-up of prostate cancer patients, including primary diagnosis, staging and biochemical recurrence. The aim of this review is to present the most important data on this novel, highly promising imaging technique, and to formulate recommendations for possible applications of (68)Ga-PSMA-11 PET/CT in clinical routine...
June 2, 2017: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28576423/-pet-ct-and-biochemical-recurrence-of-prostate-adenocarcinoma-added-value-of-68-ga-psma-11-when-18-f-fluorocholine-is-non-contributive
#20
M Gauthé, O Belissant, A Girard, J Zhang Yin, J Ohnona, A-S Cottereau, V Nataf, S Balogova, D Pontvert, T Lebret, B Guillonneau, O Cussenot, J-N Talbot
INTRODUCTION: Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose (18)F-fluorocholine (FCH) PET/CT was non-contributive. PATIENTS AND METHOD: Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of (68)Ga-PSMA-11...
June 2017: Progrès en Urologie
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"